IL6 and congenital rubella syndrome: Because of its peculiar action impairing IL-6–mediated pathogenic immunity, FDA currently approves TCZ for treatment of adult rheumatoid arthritis, large-vessel vasculitis, such as giant-cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, adult-onset Still’s disease, and the severe often life-threatening CRS induced by chimeric antigen receptor T cell therapy.